The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome

Jakub Mieszczak, Elizabeth S. Lowe, Paul Plourde, Erica Eugster

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Context: Precocious puberty (PP) in girls with McCune-Albright syndrome (MAS) is characterized by episodic development of large unilateral ovarian cysts followed by sudden onset of vaginal bleeding. Some patients experience frequent bleeding as well as accelerated linear growth and advanced skeletal maturation. The use of anastrozole for the treatment of PP in this condition has not been well studied. Objective: The objective of the study was to determine the safety and efficacy of the aromatase inhibitor anastrozole for the treatment of PP in girls with MAS. Design and Settings: This was a prospective international multicenter study in which subjects received anastrozole 1 mg daily for 1 yr. Patients: Twenty-eight girls 10 years of age or younger with MAS and progressive PP were enrolled. Main Outcome Measures: Vaginal bleeding, rate of skeletal maturation (change in bone age over change in chronological age), growth velocity, and uterine/ovarian volumes were measured. These indices were compared with a 6-month pretreatment interval. Results: No difference in vaginal bleeding(mean number of days per year) was noted. Mean change in ΔBA/ΔCA, which was 1.25 ± 0.77 at baseline, was -0.25 ± 1.02 at study end (P = 0.22). Average growth velocity z score was 1.40 ± 3.15 at study entry and 0.26 ± 2.71 at 12 months (P = 0.10). Mean ovarian/uterine volumes were unaffected by anastrozole, and no significant adverse events occurred. Conclusions: Although it appears safe, anastrozole for 1 yr was ineffective in halting vaginal bleeding, attenuating rates of skeletal maturation, and linear growth in girls with MAS. Pharmacological strategies other than anastrozole should be pursued for the treatment of PP in this population.

Original languageEnglish
Pages (from-to)2751-2754
Number of pages4
JournalJournal of Clinical Endocrinology and Metabolism
Volume93
Issue number7
DOIs
StatePublished - Jul 2008

Fingerprint

Polyostotic Fibrous Dysplasia
Precocious Puberty
Aromatase Inhibitors
Uterine Hemorrhage
Growth
Therapeutics
Ovarian Cysts
Multicenter Studies
anastrozole
Bone
Outcome Assessment (Health Care)
Pharmacology
Hemorrhage
Safety
Bone and Bones
Population

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome. / Mieszczak, Jakub; Lowe, Elizabeth S.; Plourde, Paul; Eugster, Erica.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 93, No. 7, 07.2008, p. 2751-2754.

Research output: Contribution to journalArticle

@article{395174d7968f4cf0ab864c57089b57f6,
title = "The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome",
abstract = "Context: Precocious puberty (PP) in girls with McCune-Albright syndrome (MAS) is characterized by episodic development of large unilateral ovarian cysts followed by sudden onset of vaginal bleeding. Some patients experience frequent bleeding as well as accelerated linear growth and advanced skeletal maturation. The use of anastrozole for the treatment of PP in this condition has not been well studied. Objective: The objective of the study was to determine the safety and efficacy of the aromatase inhibitor anastrozole for the treatment of PP in girls with MAS. Design and Settings: This was a prospective international multicenter study in which subjects received anastrozole 1 mg daily for 1 yr. Patients: Twenty-eight girls 10 years of age or younger with MAS and progressive PP were enrolled. Main Outcome Measures: Vaginal bleeding, rate of skeletal maturation (change in bone age over change in chronological age), growth velocity, and uterine/ovarian volumes were measured. These indices were compared with a 6-month pretreatment interval. Results: No difference in vaginal bleeding(mean number of days per year) was noted. Mean change in ΔBA/ΔCA, which was 1.25 ± 0.77 at baseline, was -0.25 ± 1.02 at study end (P = 0.22). Average growth velocity z score was 1.40 ± 3.15 at study entry and 0.26 ± 2.71 at 12 months (P = 0.10). Mean ovarian/uterine volumes were unaffected by anastrozole, and no significant adverse events occurred. Conclusions: Although it appears safe, anastrozole for 1 yr was ineffective in halting vaginal bleeding, attenuating rates of skeletal maturation, and linear growth in girls with MAS. Pharmacological strategies other than anastrozole should be pursued for the treatment of PP in this population.",
author = "Jakub Mieszczak and Lowe, {Elizabeth S.} and Paul Plourde and Erica Eugster",
year = "2008",
month = "7",
doi = "10.1210/jc.2007-2090",
language = "English",
volume = "93",
pages = "2751--2754",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "7",

}

TY - JOUR

T1 - The aromatase inhibitor anastrozole is ineffective in the treatment of precocious puberty in girls with McCune-Albright syndrome

AU - Mieszczak, Jakub

AU - Lowe, Elizabeth S.

AU - Plourde, Paul

AU - Eugster, Erica

PY - 2008/7

Y1 - 2008/7

N2 - Context: Precocious puberty (PP) in girls with McCune-Albright syndrome (MAS) is characterized by episodic development of large unilateral ovarian cysts followed by sudden onset of vaginal bleeding. Some patients experience frequent bleeding as well as accelerated linear growth and advanced skeletal maturation. The use of anastrozole for the treatment of PP in this condition has not been well studied. Objective: The objective of the study was to determine the safety and efficacy of the aromatase inhibitor anastrozole for the treatment of PP in girls with MAS. Design and Settings: This was a prospective international multicenter study in which subjects received anastrozole 1 mg daily for 1 yr. Patients: Twenty-eight girls 10 years of age or younger with MAS and progressive PP were enrolled. Main Outcome Measures: Vaginal bleeding, rate of skeletal maturation (change in bone age over change in chronological age), growth velocity, and uterine/ovarian volumes were measured. These indices were compared with a 6-month pretreatment interval. Results: No difference in vaginal bleeding(mean number of days per year) was noted. Mean change in ΔBA/ΔCA, which was 1.25 ± 0.77 at baseline, was -0.25 ± 1.02 at study end (P = 0.22). Average growth velocity z score was 1.40 ± 3.15 at study entry and 0.26 ± 2.71 at 12 months (P = 0.10). Mean ovarian/uterine volumes were unaffected by anastrozole, and no significant adverse events occurred. Conclusions: Although it appears safe, anastrozole for 1 yr was ineffective in halting vaginal bleeding, attenuating rates of skeletal maturation, and linear growth in girls with MAS. Pharmacological strategies other than anastrozole should be pursued for the treatment of PP in this population.

AB - Context: Precocious puberty (PP) in girls with McCune-Albright syndrome (MAS) is characterized by episodic development of large unilateral ovarian cysts followed by sudden onset of vaginal bleeding. Some patients experience frequent bleeding as well as accelerated linear growth and advanced skeletal maturation. The use of anastrozole for the treatment of PP in this condition has not been well studied. Objective: The objective of the study was to determine the safety and efficacy of the aromatase inhibitor anastrozole for the treatment of PP in girls with MAS. Design and Settings: This was a prospective international multicenter study in which subjects received anastrozole 1 mg daily for 1 yr. Patients: Twenty-eight girls 10 years of age or younger with MAS and progressive PP were enrolled. Main Outcome Measures: Vaginal bleeding, rate of skeletal maturation (change in bone age over change in chronological age), growth velocity, and uterine/ovarian volumes were measured. These indices were compared with a 6-month pretreatment interval. Results: No difference in vaginal bleeding(mean number of days per year) was noted. Mean change in ΔBA/ΔCA, which was 1.25 ± 0.77 at baseline, was -0.25 ± 1.02 at study end (P = 0.22). Average growth velocity z score was 1.40 ± 3.15 at study entry and 0.26 ± 2.71 at 12 months (P = 0.10). Mean ovarian/uterine volumes were unaffected by anastrozole, and no significant adverse events occurred. Conclusions: Although it appears safe, anastrozole for 1 yr was ineffective in halting vaginal bleeding, attenuating rates of skeletal maturation, and linear growth in girls with MAS. Pharmacological strategies other than anastrozole should be pursued for the treatment of PP in this population.

UR - http://www.scopus.com/inward/record.url?scp=47549102969&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47549102969&partnerID=8YFLogxK

U2 - 10.1210/jc.2007-2090

DO - 10.1210/jc.2007-2090

M3 - Article

VL - 93

SP - 2751

EP - 2754

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 7

ER -